Change in Off-Label Use of Bone Morphogenetic Protein in Spine Surgery and Associations with Adverse Outcome

Study Design Retrospective cohort study. Objective The U.S. Food and Drug Administration issued a warning in 2008 against off-label bone morphogenetic protein (BMP-2) use. We aimed to determine (off-label) BMP-2 use in two periods and associations with complications. Methods We included 340,393 pati...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Global Spine J
Asıl Yazarlar: Poeran, Jashvant, Opperer, Mathias, Rasul, Rehana, Mazumdar, Madhu, Girardi, Federico P., Hughes, Alexander P., Memtsoudis, Stavros G., Vougioukas, Vassilios
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Georg Thieme Verlag KG 2016
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5077709/
https://ncbi.nlm.nih.gov/pubmed/27781184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0036-1571284
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller